Jefferies analyst Thomas Wei cut his price target on Stemline Therapeutics (NASDAQ: STML) to $50.00 (from $60.00) but reiterated a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE